Last updated on October 2017

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Brief description of study

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.

Clinical Study Identifier: NCT03098979

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Shonan Fujisawa Tokushukai Hospital
Fujisawa, Japan
  Connect »